Science
Mechanism of Action
As a non-steroidal anti-inflammatory drug (NSAID), Sulindac primarily functions by inhibiting cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This inhibition leads to a reduction in prostaglandin synthesis, biochemicals responsible for triggering pain and inflammation. In topical applications, it has been observed to suppress overall inflammatory responses, inhibit NF-κB activation, and decrease COX-2 expression, contributing to its noted skin benefits.
Research
Clinical Evidence
Medium confidence5%
Key findings
- 01 A topical 5% Sulindac nanoemulgel exhibited significantly higher drug release (97.4±0.21%) and flux (5.29±1.20 µg/cm².h) when compared to a standard 5% Sulindac gel. This specific formulation maintained stability for 90 days when stored at 4°C.
- 02 Topical application of sulindac, in concentrations ranging from approximately 0.6% to 2.5% (1.25-5.0 mg/0.2 ml), to the dorsal skin of hairless mice resulted in a dose-dependent inhibition of UVB-induced inflammatory responses, including erythema, edema, and epidermal hyperplasia.
Transparency
Dusting Analysis
Sulindac is a prescription-only non-steroidal anti-inflammatory drug (NSAID) and is not typically used as a cosmetic ingredient, therefore the concept of 'dusting' at ineffective concentrations is not applicable in this context.
The Formula
Formulation
Stability
Sulindac demonstrates pH-dependent solubility, with minimal solubility in water that significantly increases at higher pH values, such as pH 7.4. It is highly soluble in various organic solvents including ethanol. A 5% sulindac nanoemulgel formulation was reported to be stable at a pH of 5.8 for 90 days when stored at 4°C.
Conflicts
- Known hypersensitivity to sulindac or other NSAIDs (relevant for both topical and oral exposure)
Safety
Safety Profile
Sulindac is classified as a human prescription drug (NSAID) and received initial FDA approval in 1976 for conditions like rheumatoid arthritis; it is not typically evaluated by cosmetic safety bodies like the CIR or SCCS. Severe cutaneous reactions, including exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported with sulindac. Immediate discontinuation at the onset of any rash is strongly advised. It is contraindicated in individuals with known hypersensitivity to sulindac or other NSAIDs.
Your Skin
Skin Compatibility
Our Assessment
Verdict
While topical Sulindac shows promising anti-inflammatory and photoprotective efficacy in studies, its classification as a prescription NSAID with a reported risk of severe cutaneous reactions makes its use in general skincare highly questionable and typically reserved for medical applications.
Related
Similar Ingredients
Finding similar ingredients…